Issue 2, 2019

Peptide ligand-mediated targeted drug delivery of nanomedicines

Abstract

Targeted drug delivery is emerging as a promising strategy to achieve better clinical outcomes. Actively targeted drug delivery that utilizes overexpressed receptors or antigens on diseased tissues is receiving increasing scrutiny, especially due to the uncertainty of existence of the enhanced permeability and retention (EPR) effect in cancer patients. Peptide ligands are advantageous over other classes of targeting ligands due to their accessibility of high-throughput screening, ease of synthesis, high specificity and affinity, etc. In this review, we briefly summarize the resources of peptide ligands and discuss the pitfalls and perspectives of peptide ligand-mediated targeted delivery of nanomedicines.

Graphical abstract: Peptide ligand-mediated targeted drug delivery of nanomedicines

Article information

Article type
Review Article
Submitted
23 Dit 2018
Accepted
31 Kax 2018
First published
18 Qun 2019

Biomater. Sci., 2019,7, 461-471

Peptide ligand-mediated targeted drug delivery of nanomedicines

Z. Jiang, J. Guan, J. Qian and C. Zhan, Biomater. Sci., 2019, 7, 461 DOI: 10.1039/C8BM01340C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements